1. Home
  2. XCBE vs PRLD Comparison

XCBE vs PRLD Comparison

Compare XCBE & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

XCBE

X3 Acquisition Corp. Ltd. Class A Ordinary Shares

SELL

Current Price

$10.06

Market Cap

282.1M

Sector

N/A

ML Signal

SELL

Logo Prelude Therapeutics Incorporated

PRLD

Prelude Therapeutics Incorporated

N/A

Current Price

$3.23

Market Cap

260.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
XCBE
PRLD
Founded
2025
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
282.1M
260.2M
IPO Year
2025
2020

Fundamental Metrics

Financial Performance
Metric
XCBE
PRLD
Price
$10.06
$3.23
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
★ $8.80
AVG Volume (30 Days)
37.5K
★ 243.3K
Earning Date
N/A
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 23.21
EPS
★ N/A
N/A
Revenue
N/A
★ $12,140,000.00
Revenue This Year
N/A
$74.34
Revenue Next Year
N/A
$85.56
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 73.43
52 Week Low
$9.75
$1.30
52 Week High
$10.09
$6.83

Technical Indicators

Market Signals
Indicator
XCBE
PRLD
Relative Strength Index (RSI) 74.85 34.61
Support Level $9.88 $2.69
Resistance Level N/A $3.32
Average True Range (ATR) 0.01 0.29
MACD 0.00 -0.04
Stochastic Oscillator 62.50 2.53

Price Performance

Historical Comparison
XCBE
PRLD

About XCBE X3 Acquisition Corp. Ltd. Class A Ordinary Shares

X3 Acquisition Corp Ltd is a blank check company.

About PRLD Prelude Therapeutics Incorporated

Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.

Share on Social Networks: